Country: Canada
Language: English
Source: Health Canada
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)
DR REDDY'S LABORATORIES LTD
N06DA03
RIVASTIGMINE
6.0MG
CAPSULE
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 6.0MG
ORAL
100/500
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0140521004; AHFS:
CANCELLED PRE MARKET
2022-07-13
PRODUCT MONOGRAPH PR RIVASTIGMINE TARTRATE CAPSULES 1.5 MG, 3 MG, 4.5 MG AND 6 MG CHOLINESTERASE INHIBITOR MANUFACTURED BY: DR. REDDY’S LABORATORIES LIMITED DATE OF PREPARATION : Bachepalli – 502 325 INDIA NOVEMBER 3, 2011 CONTROL #: 148321 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS..................................................................................................9 DRUG INTERACTIONS ..................................................................................................20 DOSAGE AND ADMINISTRATION ..............................................................................21 OVERDOSAGE ................................................................................................................23 ACTION AND CLINICAL PHARMACOLOGY ............................................................24 STORAGE AND STABILITY..........................................................................................26 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................26 PART II: SCIENTIFIC INFORMATION ...............................................................................28 PHARMACEUTICAL INFORMATION..........................................................................28 CLINICAL TRIALS ..........................................................................................................29 DETAILED PHARMACOLOGY .....................................................................................39 TOXICOLOGY .................. Read the complete document